Max-Planck-Gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Other

Smithkline Beecham Biologicals S.a.

Michael D Kramer

Markus M Simon

Ulrich E Schaible

Klaus Eichmann

Wallich Reinhard

Reinhard Wallich

Yves Lobet

Weimin Zhong

A pharmaceutical composition for treating Lyme disease contains an antibody as an active agent which is specific for the 24 kDa antigen (OspC) of , preferably an antibody which is specific for the 24 kDa antigen (OspC) of having the sequence shown in SEQ ID NO.2.

Medicament for treating a manifested lyme disease

The invention related to novel Borrelia, and OspA antigens derived therefrom. These antigens show little homology with know OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.

Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines

The present invention provides a vaccine against Lyme disease, wherein it contains one or more monoclonal antibodies which are specific for the 31 kD antigen (OspA) or the 34 kD antigen (OspB) of . The present invention also provides a process for obtaining this vaccine, as well as new monoclonal antibodies and antigens.

Vaccine against Lyme disease

Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and

The invention relates to novet Borrelia, and OspA antigens derived therefrom. These antigens show little homology with known OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.

The present invention provides a vaccine against Lyme disease, wherein it contains one or more monoclonal antibodies which are specific for the 31 kD antigen (OspA) or the 34 kD antigen (OspB) of Borrelia burgdorferi. The present invention also provides a process for obtaining this vaccine, as well as new monoclonal antibodies, hybridomas and antigens.

Hybridomas producing antibodies specific for lyme disease antigens OspA

The present invention provides a vaccine against Lyme disease, wherein it contains one or more monoclonal antibodies which are specific for the 31 kD antigen (OspA) or the 34 kD antigen (OspB) of Borrelia burgdorferi. The present invention also provides a process for obtaining this vaccine, as well as new monoclonal anti-bodies and antigens.

Passive vaccine against Lyme disease

A vaccine against Lyme disease, wherein it contains one or more monoclonal antibodies which are specific for the 31 kD antigen (OspA) or the 34 kD antigen (OspB) of Borrelia burgdorferi. The present invention also provides a process for obtaining this vaccine, as well as new monoclonal antibodies and antigens.

Nucleic acid molecule encoding antigen associated with lyme disease

The present invention provides a vaccine against Lyme disease, wherein it contains one or more monoclonal antibodies which are specific for the 31 kD antigen (OspA) or the 34 kD antigen (OspB) of Borrelia burgdorferi. The present invention also provides a process for obtaining this vaccine, as well as new monoclonal antibodies and antigens.

Growing community of inventors

Pfungstadt, Germany

Michael D Kramer